Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.

Leukemia research - 1 Dec 2011

Singh Harshabad, Asali Salma, Werner Lillian L, DeAngelo Daniel J, Ballen Karen K, Amrein Philip C, Wadleigh Martha, Galinsky Ilene, Neuberg Donna S, Fox Edward A, Stone Richard M, Attar Eyal C

Abstract excerpt

AML patients under the age of 60 whose blasts harbor a FLT3 internal tandem duplication (ITD) mutation have a higher relapse rate and inferior survival compared to those without this mutation. To determine if FLT3ITD also carries a negative prognostic impact in older adults receiving therapies commonly used in this age group, we retrospectively analyzed outcomes of patients ≥60 years with CN-AML according to FLT3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytogenetic Analysis

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Prognosis

Share to Survival Analysis

Share to Tandem Repeat Sequences

Source

Open in PubMed Open full text

Identifiers

PMID: 21696826
DOI: 10.1016/j.leukres.2011.05.032
PMCID: PMC3498766

Genes

FLT3
SCT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations.PMID 21696826Read ↗

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studySemantic proximity Read ↗

FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype.Semantic proximity Read ↗

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors.Semantic proximity Read ↗

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.Semantic proximity Read ↗

Age-dependent clinical, molecular, and prognostic differences in patients with AML: a retrospective study.Semantic proximity Read ↗

AML in the Elderly - When less may be more.Semantic proximity Read ↗

Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations.Semantic proximity Read ↗

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adultsSemantic proximity Read ↗

Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.Semantic proximity Read ↗

Genetic alterations and their clinical implications in older patients with acute myeloid leukemia.Semantic proximity Read ↗

Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).Semantic proximity Read ↗

Controversies in the Management of AML in Older Patients: A Canadian Perspective.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.